IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

Sales for IDEXX's companion animal group unit, its biggest unit which offers diagnostics for pets and IT services to veterinary clinics, rose about 6% to $870.47 million. IDEXX forecast full-year ...

Baron Funds, an investment management company, released its “Baron Asset Fund” fourth quarter 2024 investor letter. A copy of ...

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa ...

The Companion Animal Group diagnostics segment registered a 6% growth, driving the overall positive earnings performance. Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by ...

IDEXX Laboratories exceeded fourth-quarter profit and revenue estimates on sales of its animal testing products and price increases.

IDEXX Laboratories, Inc.’s IDXX fourth-quarter performance was driven by the consistent strong performance of the Companion Animal Group (“CAG”) segment. Solid performance in the international markets ...

Truist Financial Corp grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 13.9% in the 4th ...

The positive results were largely driven by strong growth in its Companion Animal Group (CAG) segment. Overall, Idexx enjoyed a solid quarter, reflecting its continuous progress and success in its ...